Amarillo Biosciences, Inc. (ABI) is a specialty biopharmaceutical company. The Company is engaged in developing biologics for the treatment of human and animal diseases. As of December 31, 2013, its focus is research aimed at the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon alpha that is administered in a low dose oral form. As of December 31, 2013, the Company owned or licensed five issued patents related to the low-dose oral delivery of interferon and one issued patent on its dietary supplement, Maxisal. The Company has completed more than 100 pre-clinical (animal) and human studies on the safety and efficacy of low-dose orally administered interferon. The Company also has a dietary supplement product, Maxisal that is useful in the symptomatic relief of dry mouth.